File:Thalidomide destabilizes CD147.jpg

Thalidomide destabilizes CD147 to cause Teratogenicity

CD147 - (basin, BSG)

a) Top, representative images of zebrafish larvae that were treated with either DMSO or 400 μM thalidomide (Thal) and analyzed at 3 d post fertilization (d.p.f.); anterior to the left, dorsal view. The dashed lines demarcate the eyes.

Thalidomide (and the derivatives lenalidomide and pomalidomide) are treatments for hematologic malignancies, multiple myeloma (MM) and del(5q) myelodysplastic syndrome (MDS). Cereblon (CRBN) is a substrate receptor of the CRL4 ubiquitin ligase complex and is the primary target by which they mediate anticancer and teratogenic effects. The ubiquitin-independent physiological chaperone-like function of CRBN that promotes maturation of the CD147 and solute carrier family 16 member 1 (SLC16A1; also known as MCT1) proteins. (text modified form abstract)

Reference

<pubmed>27294876</pubmed>

Copyright

Reprinted by permission from Macmillan Publishers Ltd: Nature Medicine (Eichner R, Heider M, Fernández-Sáiz V, van Bebber F, Garz AK, Lemeer S, Rudelius M, Targosz BS, Jacobs L, Knorn AM, Slawska J, Platzbecker U, Germing U, Langer C, Knop S, Einsele H, Peschel C, Haass C, Keller U, Schmid B, Götze KS, Kuster B, Bassermann F. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity), copyright (2016).

Figure 6 Nm.4128-F6.jpg resized and PMID added.

Licensee: Mark A Hill License Date: Jun 16, 2016 License Number: 3891130012769 Publication: Nature Medicine Title: Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity Type Of Use: post on a website Total: 0.00 USD